These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 20615907)
1. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats. Renken C; Fischer DC; Kundt G; Gretz N; Haffner D Nephrol Dial Transplant; 2011 Jan; 26(1):92-100. PubMed ID: 20615907 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708 [TBL] [Abstract][Full Text] [Related]
4. Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats. Sabbatini M; Russo L; Cappellaio F; Troncone G; Bellevicine C; De Falco V; Buonocore P; Riccio E; Bisesti V; Federico S; Pisani A Am J Physiol Renal Physiol; 2014 May; 306(10):F1243-50. PubMed ID: 24647711 [TBL] [Abstract][Full Text] [Related]
5. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease. Wu M; Arcaro A; Varga Z; Vogetseder A; Le Hir M; Wüthrich RP; Serra AL Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1597-605. PubMed ID: 19776171 [TBL] [Abstract][Full Text] [Related]
6. Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease. Berthier CC; Wahl PR; Le Hir M; Marti HP; Wagner U; Rehrauer H; Wüthrich RP; Serra AL Nephrol Dial Transplant; 2008 Mar; 23(3):880-9. PubMed ID: 18042615 [TBL] [Abstract][Full Text] [Related]
7. Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment. Ponticelli C; Locatelli F Nephrol Dial Transplant; 2010 Dec; 25(12):3809-12. PubMed ID: 20798121 [No Abstract] [Full Text] [Related]
8. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease. Wüthrich RP; Kistler AD; Serra AL Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452 [TBL] [Abstract][Full Text] [Related]
9. Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. Novalic Z; van der Wal AM; Leonhard WN; Koehl G; Breuning MH; Geissler EK; de Heer E; Peters DJ J Am Soc Nephrol; 2012 May; 23(5):842-53. PubMed ID: 22343118 [TBL] [Abstract][Full Text] [Related]
13. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. Patsenker E; Schneider V; Ledermann M; Saegesser H; Dorn C; Hellerbrand C; Stickel F J Hepatol; 2011 Aug; 55(2):388-98. PubMed ID: 21168455 [TBL] [Abstract][Full Text] [Related]
14. The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin. Stylianou K; Petrakis I; Mavroeidi V; Stratakis S; Vardaki E; Perakis K; Stratigis S; Passam A; Papadogiorgaki E; Giannakakis K; Nakopoulou L; Daphnis E Nephrol Dial Transplant; 2011 Feb; 26(2):498-508. PubMed ID: 20709738 [TBL] [Abstract][Full Text] [Related]
15. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448 [TBL] [Abstract][Full Text] [Related]
16. Sirolimus reduces polycystic liver volume in ADPKD patients. Qian Q; Du H; King BF; Kumar S; Dean PG; Cosio FG; Torres VE J Am Soc Nephrol; 2008 Mar; 19(3):631-8. PubMed ID: 18199797 [TBL] [Abstract][Full Text] [Related]
17. mTOR partly mediates insulin resistance by phosphorylation of insulin receptor substrate-1 on serine(307) residues after burn. Xin-Long C; Zhao-Fan X; Dao-Feng B; Wei D Burns; 2011 Feb; 37(1):86-93. PubMed ID: 20594757 [TBL] [Abstract][Full Text] [Related]
18. Randomized intervention studies in human polycystic kidney and liver disease. Schrier RW J Am Soc Nephrol; 2010 Jun; 21(6):891-3. PubMed ID: 20431043 [No Abstract] [Full Text] [Related]
19. mTOR inhibition and erythropoiesis: microcytosis or anaemia? Diekmann F; Rovira J; Diaz-Ricart M; Arellano EM; Vodenik B; Jou JM; Vives-Corrons JL; Escolar G; Campistol JM Nephrol Dial Transplant; 2012 Feb; 27(2):537-41. PubMed ID: 21785038 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of intrahepatic bile duct dilation of the polycystic kidney rat with a novel tyrosine kinase inhibitor gefitinib. Sato Y; Harada K; Furubo S; Kizawa K; Sanzen T; Yasoshima M; Ozaki S; Isse K; Sasaki M; Nakanuma Y Am J Pathol; 2006 Oct; 169(4):1238-50. PubMed ID: 17003482 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]